As part of a joint effort with the FDA to streamline regulatory oversight of gene therapy development, the NIH is proposing to end some of its activities that duplicate FDA requirements. "With the evolution of the field of gene therapy, duplication in reviews and paperwork have sometimes occurred without a commensurate increase in protecting participant safety," the NIH said.